Features | Partner Sites | Information | LinkXpress
Sign In

Dominant Gene Mutations Causes Van der Woude Syndrome

By Labmedica International staff writers
Posted on 01 Jan 2014
Image: An 8-month-old infant with an extensive cleft palate associated with the genetic condition Bamforth- Lazarus syndrome (Photo courtesy of Maynika V Rastogi and Stephen H LaFranchi).
Image: An 8-month-old infant with an extensive cleft palate associated with the genetic condition Bamforth- Lazarus syndrome (Photo courtesy of Maynika V Rastogi and Stephen H LaFranchi).
A new gene has been identified that is related to the Van der Woude syndrome, the most common syndrome with cleft lip and palate.

There are more than 350 syndromes with clefts, of which Van der Woude syndrome (VWS) is the most common and approximately 70% of the individuals with VWS have a mutation in a gene called interferon regulatory factor 6 (IRF6).

An international team led by scientists from the Karolinska Institute (Huddinge, Sweden) collected DNA samples from 45 families of multiple ethnicities who were completely sequenced for IRF6 without identifying a causative mutation. A total of 360 unrelated individuals without a history of oral cleft from the Philippines were used as controls.

The team started by executing a genetic linkage study of a large family from Finland. The family had been diagnosed with VWS, although no IRF6 mutations had been found. By comparing the DNA of affected individuals with DNA from healthy family members, the scientists identified another gene, called Grainy-head like 3 (GRHL3), which was mutated only in the affected family members. The same gene was found to be altered in seven additional families with VWS where no IRF6 mutations had been found previously.

Genomic DNA from eight affected and three healthy individuals from the VWS Finnish family underwent SureSelect Target Enrichment (Agilent Technologies, Santa Clara, CA, USA) in order to perform sequence capture of the exome. Enriched samples were sequenced on an Illumina HiSeq instrument (San Diego, CA, USA). Genotyping, mutation screening by Sanger sequencing, phenotyping, and other studies were also performed. The authors conclude that both genes are required for a proper formation of the palate, probably functioning in separate but convergent molecular pathways. The study highlights the importance of studying even rare patients to increase our understanding of disease mechanisms.

Myriam Peyrard-Janvid, PhD, the senior author of the study said, “The discovery of a new gene, GRHL3, responsible for the most common of the syndromic forms of cleft lip and palate means that clinicians with collections of families or isolated cases with cleft lip and palate, syndromic or non-syndromic, now will be able to look for mutations in this gene. As it has been shown for IRF6, one or several polymorphisms in GRHL3 might be found to be associated with increased risk of clefts in nonsyndromic cases.” The study was published on December 19, 2013, in the American Journal of Human Genetics.

Related Links:

Karolinska Institute
Agilent Technologies




view channel

Blood Donations Screened for Viruses Using Multiplex Assay

A global healthcare company was chosen to partner the Japanese Red Cross (JRC; Tokyo, Japan) for nucleic acid screening of the nation's blood supply. Under the terms of the 7-year agreement, the healthcare company, Grifols (Barcelona, Spain) will provide the JRC with its newest automation platform, the Procleix Panther... Read more


view channel

Gene Profile Predicts Risk of Bladder Cancer Recurrence

A genomic study has pinpointed several markers that identify bladder cancer patients at risk of recurrence and that may be indicators of overall survival status. Nearly half of patients with bladder cancer experience recurrences, so reliable predictors of this recurrent phenotype are needed to guide surveillance and treatment.... Read more

Industry News

view channel

Roche Acquires IQuum, Strengthens Diagnostics Offerings with Unique System

The acquisition by Roche (Basel, Switzerland) of IQuum, Inc. (Marlborough, MA, USA) will enable Roche to more quickly enter the point-of-care (POC) segment of molecular diagnostics with products based on IQuum proprietary lab-in-tube technology. The technology underlies a novel biological sample testing platform that enables... Read more
Copyright © 2000-2014 Globetech Media. All rights reserved.